Spero Therapeutics (NASDAQ:SPRO – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.01, Zacks reports. The firm had revenue of $10.20 million during the quarter, compared to analyst estimates of $9.80 million. Spero Therapeutics had a net margin of 21.09% and a return on equity of 35.42%. During the same quarter in the previous year, the business posted ($0.23) EPS.
Spero Therapeutics Trading Up 1.6 %
NASDAQ:SPRO traded up $0.02 during trading hours on Wednesday, reaching $1.29. 137,744 shares of the company were exchanged, compared to its average volume of 221,991. The stock’s 50-day moving average is $1.38 and its 200-day moving average is $1.51. The firm has a market cap of $69.65 million, a PE ratio of 2.97 and a beta of 0.63. Spero Therapeutics has a twelve month low of $0.99 and a twelve month high of $1.89.
Analysts Set New Price Targets
Several analysts have weighed in on SPRO shares. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Spero Therapeutics in a research report on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a research note on Tuesday. Finally, TD Cowen upgraded shares of Spero Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday.
Spero Therapeutics Company Profile
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.
See Also
- Five stocks we like better than Spero Therapeutics
- Best Stocks Under $5.00
- What Are Bonds? A High-Level Overview
- What does consumer price index measure?
- Super Micro Stock Drops Sharply After Earnings on Margin Concerns
- Where Do I Find 52-Week Highs and Lows?
- Lyft’s First-Ever Profit, but the Outlook Is a Speed Bump
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
